A novel orally administered trimebutine compound (GIC ‐1001) is anti‐nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide‐releasing capacity in mice
Abstract
Background Trimebutine maleate, a noncompetitive spasmolytic agent with some affinity for peripheral μ‐ and κ‐opioid receptors has been evaluated as a treatment in a limited number of patients undergoing sedation‐free full colonoscopy. The efficiency of such treatment was comparable to sedation‐based colonoscopies to relieve from pain and discomfort. Methods A new and improved trimebutine salt capable of releasing in vivo hydrogen sulphide (H 2...
Paper Details
Title
A novel orally administered trimebutine compound (GIC ‐1001) is anti‐nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide‐releasing capacity in mice
Published Date
Nov 6, 2015
Journal
Volume
20
Issue
5
Pages
723 - 730
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History